8-K filing — PROCEPT BioRobotics Corp (PRCT)
Filed: 2026-09-24 AccNo: 0001588978-26-000034 Size: 170 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Piper Sandler Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $25
Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $35 to $25.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Important Notice to Long-Term Shareholders of Doximity, Inc. (NYSE: DOCS); GoDaddy Inc. (NYSE: GDDY); Planet Fitness, Inc. (NYSE: PLNT); and PROCEPT BioRobotics Corporation (NASDAQ: PRCT): Grabar Law Office is Investigating Claims on Your Behalf
Grabar Law Office announced investigations into potential breaches of fiduciary duties by officers and directors at Doximity, GoDaddy, Planet Fitness, and PROCEPT BioRobotics. The investigations follow federal securities class action filings alleging misleading statements regarding business metrics, pricing strategies, and financial guidance. Long-term shareholders meeting specific holding periods are eligible to seek corporate reforms and potential compensation at no cost.
Kaplan Fox Encourages PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors Seeking Recovery to Contact the Firm Before September 22, 2026
Kaplan Fox has filed a class action lawsuit against PROCEPT BioRobotics Corporation for allegedly misleading investors about the relationship between handpiece unit sales and procedures. The complaint alleges that undisclosed discount programs artificially inflated reported U.S. handpiece unit sales and revenues by pulling forward demand. Investors who purchased PROCEPT common stock between February 28, 2024 and February 25, 2026 may be eligible to participate in the class action, with a deadline of September 22, 2026 to seek a lead plaintiff role.
Bragar Eagel & Squire, P.C Urges PROCEPT BioRobotics Corporation Investors to Contact the Firm Seeking Lead Plaintiff Role Before September 22nd
A class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements regarding its handpiece unit sales and revenues. The company allegedly used an undisclosed extensive discount program to artificially inflate sales by pulling forward orders, creating over 10,000 excess units in field inventory and causing the company to miss its 2025 guidance. Investors who purchased stock between February 28, 2024 and February 25, 2026 can apply to be lead plaintiff by September 22, 2026.